Business

Know the Business

Molina is a pure-play government-insurance underwriter: it takes a fixed per-member-per-month (PMPM) premium from state Medicaid agencies, CMS, and the ACA Marketplace, and assumes the risk that actual medical costs come in below that rate. It looks like an insurance company; it behaves like a state-regulated utility whose customer is a government, whose price is set in actuarial rate filings, and whose only operational lever for differentiation is medical-cost control. The market may be overestimating how cyclical the 2025 margin collapse is — Medicaid rate-trend cycles have normalized within 18–24 months historically — but underestimating the secular headwind from OBBBA and Marketplace subsidy expiry, which permanently shrinks two of the three revenue engines into 2027–2029.

1. How This Business Actually Works

Molina's economic engine is PMPM × members × MCR discipline, repeated across three regulated buyers. There is no pricing power on the revenue line — premiums are set in rate books filed with states, CMS, and HHS. All the operating skill goes into pulling medical costs below the actuary's assumption.

If state actuaries underestimate next year's cost trend by 250 basis points (which is what happened in 2024–25), Molina's pretax earnings get cut roughly in half. Conversely, when rates catch up to trend — typically over 12–18 months — the same lever swings the other way. Underwriting margin is not where Molina makes its money; it's where it avoids losing its money. Real value compounds through three other mechanics: float on $8.3B of regulated cash and investments, fixed-cost absorption on G&A as premium revenue scales, and incumbency leverage at re-procurement.

2. The Playing Field

Molina is the smallest pure-play government MCO in a sector dominated by vertically integrated giants. UNH and CVS earn money in three places (premium, PBM, care delivery); Molina earns it in one. That focus is the strategy: Molina bids the lowest cost structure into Medicaid procurements and accepts that it will never own the rest of the value chain.

On a return-on-capital basis, Molina even in a trough year sits in the upper half of the group, ahead of CNC (which lost $6.4B), CVS, and HUM.

Three things to hold onto from the peer table. First, the vertically integrated giants (UNH, CVS) trade at higher revenue multiples because they capture margin pools outside the premium line — Optum and Caremark earn services dollars unrelated to MCR. Second, CNC is the truest economic comp for Molina — government-program focus, similar 75/15/10 mix — but CNC is trading through a deeper crisis (FY2025 loss of $6.4B) which makes its multiple unreliable. Third, ELV trades at 16x earnings with 13% ROE because its commercial book provides diversification Molina lacks; that's the structural valuation gap Molina cannot close without becoming a different company.

What "good" looks like in this group is MCR discipline through a cycle, RFP win rate over a five-year window, and capital returned to shareholders without depleting subsidiary capital surplus. Molina has historically led on the first and third; CNC and ELV lead on the second by virtue of scale and incumbency.

3. Is This Business Cyclical?

The cycle in managed care is a rate-versus-trend cycle, not industrial. Medical-cost utilization rises continuously; rates re-price on a 9–18 month lag. Margins compress when actuaries underestimate next year's trend, then snap back as states and CMS catch up. Molina has been through this twice in eight years and the pattern is identical both times.

Where the cycle hits first is the consolidated MCR. Where it hits last is enterprise value — the equity already priced in by Q4 2025, when the stock fell from a 52-week high near $360 to below $180. Working capital is a positive cycle attribute for Molina: as rates catch up, premium receivables refresh quickly, and the float on $8.3B of cash/investments earns through it.

4. The Metrics That Actually Matter

Forget revenue growth and EPS. The three or four numbers that decide whether Molina creates or destroys value are operational, not financial.

The metric most outsiders track — EV/Revenue at 0.09x — is almost meaningless here because EV is artificially low (Yahoo treats Molina's $8.3B regulated-investment portfolio as cash equivalents, which is technically correct but economically misleading: that portfolio belongs to regulated subsidiaries and cannot be freely dividended). The cleaner read is enterprise revenue multiple stripped of regulatory capital, or simply forward P/E on normalized earnings.

5. What Is This Business Worth?

The right valuation lens is normalized through-cycle after-tax margin × premium revenue × earnings multiple, with an explicit haircut for OBBBA-related revenue base contraction. Not SOTP — the three segments share members, infrastructure, regulators, and capital, and their economics are not separable. The "Other" segment is immaterial. There is no listed subsidiary, no investment stake, no holdco discount to argue about.

Conditions that would support the cheap read: a clean Q3 2026 MCR print below 91% in Medicaid, a state-level rate notice in California or New York above 5%, and visible buyback continuation at current prices. Conditions that would refute it: a second top-5 state contract loss, an acceleration of OBBBA work-requirement implementation into 2027, or a Star Ratings setback shrinking Medicare bonus payments below the already-reduced 2026 base.

6. What I'd Tell a Young Analyst

Track the rate book, not the consensus. Every state publishes its Medicaid rate update at predictable points; CMS publishes its Medicare Advantage rate notice each April. Build a spreadsheet that compares the rate update to the company's stated medical-cost trend assumption. When that gap closes, EPS estimates move 60-90 days later.

The moat is incumbency, not scale. Molina's competitive advantage is that re-procurement decisions are made by state agencies who know the incumbent's clinical model, claims-payment reliability, and provider relationships. The 90% renewal rate is the moat. The day that drops below 80% — as it briefly did in 2017 — the franchise is being repriced, not just the earnings.

Do not pay for "embedded earnings" as if they were realized. Management's $2.50/share of embedded earnings (MAPD exit losses + Florida CMS implementation) is real but is a 2027 phenomenon. Until it shows up in cash, treat it as call-option value, not base earnings.

The Virginia loss matters more than the Florida win. The market will not punish Molina for a small contract loss on its own, but it shifts the prior on RFP win rate. Watch the cadence of state-level wins and losses over a five-year window. A run of two top-5 losses in 18 months would mean something the consensus model isn't pricing.

Read the MCR with the segment lens, not the consolidated lens. Consolidated MCR moves slowly because Medicaid is 75% of revenue. Marketplace MCR can swing 1500bps in a year (75.4 → 89.0 in 2024 to 2025) and Medicare MCR is what determines whether the dual-eligible strategy is working. The interesting tape reading is segment MCR relative to segment guidance.

Finally, respect the regulatory tape. A single line in an HHS rule, a single CMS rate notice, or a single state RFP outcome can reset the next 12 months of earnings. The investor who watches the Federal Register more closely than the earnings calendar usually gets paid.